$ADAG To Share Updated Clinical Data From ADG126 In Microsatellite Stable Colorectal Cancer At ASCO Gastrointestinal Cancers Symposium On January 25, 2025.Adagene will present updated clinical data for ADG126 in microsatellite stable (MSS) colorectal cancer at the ASCO Gastrointestinal Cancers Symposium on January 25, 2025. ADG126 is a novel immunotherapy being evaluated for its potential in treating MSS colorectal cancer. The presentation will focus on the latest findings from ongoing clinical trials. These results could offer important insights into ADG126’s efficacy and safety. The company aims to showcase the treatment’s potential to improve outcomes in this challenging cancer type. The symposium provides a platform for Adagene to share its progress with the oncology community. This update is anticipated to generate interest among researchers and investors. Adagene is advancing its pipeline with promising therapies like ADG126. #StockMarket
#adag
#ADAG